Skip to main content
. 2021 Jun 16;6(4):100190. doi: 10.1016/j.esmoop.2021.100190

Figure 2.

Figure 2

Survival analysis of patients treated with lenvatinib based on risk groups identified with recursive partitioning analysis (RPA).

(A) Median overall survival (OS) was 29.8 months [95% confidence interval (CI) 22.8-29.8 months] in the low risk group, 17.0 months (95% CI 15.0-24.0 months) in medium risk and 8.9 months (95% CI 8.0-10.7 months) in high risk; low risk hazard ratio (HR) 1, medium risk HR 1.95 (95% CI 1.38-2.74), high risk HR 4.84 (95% CI 3.16-7.43); P < 0.0001. (B) Median progression-free survival (PFS) was 7.2 months (95% CI 6.0-9.4 months) in the low risk group, 6.9 months (95% CI 5.9-7.9 months) in medium and 3.0 months (95% CI 2.5-4.7 months) in high risk; low risk HR 1, medium risk HR 1.00 (95% CI 0.78-1.30), high risk HR 2.04 (95% CI 1.46-2.84); P < 0.0001.